Linagliptine Aurobindo

Linagliptin, the active ingredient in Linagliptine Aurobindo, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients.

GNH USA supplies Linagliptine Aurobindo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptine Aurobindo is a DPP-4 inhibitor indicated for the management of type 2 diabetes mellitus and related therapeutic pathways. - Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Combination therapy with other antidiabetic agents: enhances overall glucose lowering when added to metformin, sulfonylureas, or insulin. - Adjunct to diet and exercise: supports blood sugar management as part of a comprehensive lifestyle plan.

Linagliptine Aurobindo may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: mild nausea or abdominal pain. - Back pain: occasional musculoskeletal ache.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain, nausea, and vomiting requiring immediate medical attention. - Severe allergic reactions: including angioedema, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: rare skin blistering disorder. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas.

Before initiating Linagliptine Aurobindo, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and follow prescriber guidance for dose adjustment. - Hepatic impairment: monitor liver enzymes regularly. - Risk of hypoglycemia: heightened when used with insulin or sulfonylureas; educate patients on signs. - Pancreatitis: discontinue if persistent abdominal pain or elevated pancreatic enzymes occur. - Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Linagliptine Aurobindo can interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: may cause significant hypoglycemia. - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure and efficacy.

Moderate Interactions (Monitor Closely):\n- Diuretics: may affect glucose control; monitor blood glucose. - ACE inhibitors or ARBs: observe blood pressure and renal function. - Warfarin: periodic INR checks recommended.